market access

News

NICE says 'no' to Pfizer's Vyndaqel for rare heart condition

NICE has rejected regular NHS funding for Pfizer’s Vyndaqel (tafamidis) for a rare heart condition, although it has left the door open for negotiations if the pharma decid

Views & Analysis

Research predicts the post-COVID landscape for HCP engagemen...

IQVIA’s Liz Murray takes us through the company’s latest research into HCPs’ attitudes to pharma engagement, and asks how pharma sales forces can adapt for future changes.

Views & Analysis

A year on: pandemic driven trends in HCP engagement

IQVIA’s John Procter explores why the industry should be paying attention to the changing HCP customer experience in the wake of COVID-19.

News

AstraZeneca's (AZ) Tagrisso (osimertinib)

Patients in England get fast access to AZ's Tagrisso in earl...

The UK’s drugs regulator has swiftly granted a licence extension for AstraZeneca’s Tagrisso in certain patients with early stage lung cancer, with NICE allowing fast access to patients on E

Views & Analysis